These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 29271513

  • 1. Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer.
    Bai M, Song N, Che X, Wang X, Qu X, Liu Y.
    Cell Biol Int; 2018 Jul; 42(7):781-793. PubMed ID: 29271513
    [Abstract] [Full Text] [Related]

  • 2. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
    Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR.
    Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
    [Abstract] [Full Text] [Related]

  • 3. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
    Kim JW, Kim HP, Im SA, Kang S, Hur HS, Yoon YK, Oh DY, Kim JH, Lee DS, Kim TY, Bang YJ.
    Cancer Lett; 2008 Dec 18; 272(2):296-306. PubMed ID: 18774637
    [Abstract] [Full Text] [Related]

  • 4. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
    Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ, Finn RS.
    Clin Cancer Res; 2010 Mar 01; 16(5):1509-19. PubMed ID: 20179222
    [Abstract] [Full Text] [Related]

  • 5. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
    Kim HP, Han SW, Song SH, Jeong EG, Lee MY, Hwang D, Im SA, Bang YJ, Kim TY.
    Oncogene; 2014 Jun 19; 33(25):3334-41. PubMed ID: 23873022
    [Abstract] [Full Text] [Related]

  • 6. EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.
    Mizukami T, Togashi Y, Sogabe S, Banno E, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Nakajima TE, Boku N, Nishio K.
    Int J Oncol; 2015 Aug 19; 47(2):499-505. PubMed ID: 26081723
    [Abstract] [Full Text] [Related]

  • 7. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
    Guo XF, Zhu XF, Zhong GS, Deng BG, Gao ZT, Wang H.
    Oncol Rep; 2012 May 19; 27(5):1639-45. PubMed ID: 22293713
    [Abstract] [Full Text] [Related]

  • 8. HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells.
    Park KS, Hong YS, Choi J, Yoon S, Kang J, Kim D, Lee KP, Im HS, Lee CH, Seo S, Kim SW, Lee DH, Park SR.
    BMB Rep; 2018 Dec 19; 51(12):660-665. PubMed ID: 30591093
    [Abstract] [Full Text] [Related]

  • 9. A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells.
    Tian C, Ding P, Yuan Z, Li H, Zhao Y, Sun L, Guo Q, Wang Z, Sun L, Zhang L, Jiang Z.
    Apoptosis; 2015 Dec 19; 20(12):1599-612. PubMed ID: 26437915
    [Abstract] [Full Text] [Related]

  • 10. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
    Guo XF, Zhu XF, Zhong GS, Deng BG.
    Dis Esophagus; 2013 Jul 19; 26(5):487-95. PubMed ID: 22458639
    [Abstract] [Full Text] [Related]

  • 11. Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells.
    Sato Y, Yashiro M, Takakura N.
    Cancer Sci; 2013 Dec 19; 104(12):1618-25. PubMed ID: 24112719
    [Abstract] [Full Text] [Related]

  • 12. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J, Okamoto I, Fumita S, Okamoto W, Nishio K, Nakagawa K.
    Oncogene; 2011 Sep 29; 30(39):4097-106. PubMed ID: 21499301
    [Abstract] [Full Text] [Related]

  • 13. A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer.
    Ning G, Zhu Q, Kang W, Lee H, Maher L, Suh YS, Michaud M, Silva M, Kwon JY, Zhang C, Lee C.
    BMC Cancer; 2021 Aug 16; 21(1):923. PubMed ID: 34399705
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines.
    Oshima Y, Tanaka H, Murakami H, Ito Y, Furuya T, Kondo E, Kodera Y, Nakanishi H.
    Gastric Cancer; 2014 Aug 16; 17(3):450-62. PubMed ID: 23948998
    [Abstract] [Full Text] [Related]

  • 16. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH, Ito K, Olcott W, Katsyv I, Halstead-Nussloch G, Irie HY.
    Breast Cancer Res; 2015 Jun 19; 17(1):86. PubMed ID: 26084280
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.